Stay Alert for Safety Issues With Xeljanz and Other "JAK Inhibitors"

Questions will pop up about the safety of "Janus kinase (JAK) inhibitors"...Xeljanz, Olumiant, and the newly approved Rinvoq.

There's an uptick in use of these specialty meds for rheumatoid arthritis and other autoimmune diseases...since they're taken orally.

Now there's a boxed warning about an increased risk of blood clots with Xeljanz (tofacitinib). Olumiant (baricitinib) and Rinvoq (upadacitinib) also carry this warning.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote